Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Rheumatology

What is the Difference Between Limited and Systemic GPA?

At a Glance

The main difference between limited and systemic Granulomatosis with Polyangiitis (GPA) is organ involvement. Limited GPA is primarily confined to the respiratory tract, while systemic GPA is widespread and critically affects major internal organs, most notably causing severe kidney inflammation.

Granulomatosis with polyangiitis (GPA) is not exactly the same for everyone who has it; it exists on a spectrum of severity [1]. The main difference between “limited” (or localized) GPA and “systemic” (or generalized) GPA comes down to which organs are affected and whether the inflammation is immediately threatening your major internal organs [2]. Simply put, limited GPA is typically confined to the upper or lower respiratory tracts—such as the nose, sinuses, ears, and lungs—and does not involve severe, organ-threatening damage to the kidneys [2][1]. In contrast, systemic GPA is a more widespread disease that affects multiple organ systems, most notably causing dangerous inflammation in the kidneys [1][3].

About 10% of people diagnosed with GPA have the limited form at the time of their diagnosis [4]. While “limited” sounds less serious, it can still cause significant, hard-to-treat symptoms and requires careful monitoring by your care team [5].

What is Limited GPA?

If your doctor says you have limited GPA, it means the inflammation has not caused severe damage to your kidneys or other critical internal organs [2]. People with limited GPA tend to be diagnosed at a slightly younger age [4].

The symptoms are primarily restricted to the respiratory system, which includes:

  • Upper respiratory tract: Chronic sinus infections, intense nasal crusting, nosebleeds, ear pain, or hearing loss [6]. Sometimes it leads to specific complications like a collapsed nasal bridge (saddle nose deformity) or a dangerous narrowing of the windpipe (subglottic stenosis) [4]. Because symptoms are concentrated here, an ENT (Ear, Nose, and Throat) specialist is often a crucial part of the care team.
  • Lower respiratory tract: Nodules or mild inflammation in the lungs [7]. Unlike systemic GPA, these lung issues are typically not immediately life-threatening, but they still require treatment [2].
  • Eyes: Redness, pain, or changes in vision [6].

Even though it avoids the kidneys, limited GPA is known for being stubborn. It frequently relapses (flares up) in the ear, nose, throat, or lungs, even after treatment [5][4].

What is Systemic GPA?

Systemic (generalized) GPA means the disease has spread to multiple systems in the body, most critically the kidneys [1][3].

  • Kidney involvement (Glomerulonephritis): This is inflammation of the tiny filters in the kidneys. It is a hallmark of systemic GPA and often doesn’t cause obvious symptoms early on, which is why doctors monitor urine tests so closely [3]. If left untreated, kidney involvement can lead to significant organ damage and increases the risk of mortality [8][9].
  • Pulmonary-renal syndrome: Many people with systemic GPA experience severe, bleeding inflammation in the lungs (alveolar hemorrhage) at the same time as kidney inflammation [10].

Differences in ANCA Blood Tests

To help diagnose GPA, doctors test for ANCA (antineutrophil cytoplasmic antibodies), which are autoantibodies that mistakenly attack the body’s own cells [11].

  • In systemic GPA, the vast majority of patients test positive for a specific type of ANCA called PR3-ANCA [12][13]. A smaller percentage of patients may test positive for another type called MPO-ANCA [14].
  • In limited GPA, patients are much more likely to be ANCA-negative (meaning the antibodies don’t show up on the blood test) or have lower rates of PR3-ANCA positivity [15][4].

This difference in blood tests means limited GPA can sometimes be trickier to diagnose quickly if the doctor is heavily relying on a positive ANCA result to confirm the disease [16].

Can Limited GPA Progress to Systemic GPA?

Yes. “Limited” is a description of how the disease is acting right now, not a guarantee of how it will act forever [10]. Research shows that over a period of a few years, about 23% of patients with limited GPA progress to systemic GPA [4]. This progression usually happens when the disease relapses or becomes resistant to initial treatments [4].

Because of this risk, your care team will continually monitor your kidney function with routine blood and urine tests—usually every 1 to 3 months, depending on how active your disease is—even if your kidneys are currently perfectly healthy [8].

How the Distinction Affects Treatment

Because systemic GPA aggressively threatens the kidneys and other major organs, it typically requires stronger, faster-acting immunosuppressive treatments right from the start, such as cyclophosphamide or rituximab [4][17].

For limited GPA, doctors might start with slightly less aggressive systemic medications, such as methotrexate, to control the underlying inflammation [4]. However, if limited GPA is stubborn, relapses frequently, or doesn’t respond well to methotrexate, your doctor may step up your treatment to stronger medications like rituximab [7][18].

Regardless of whether you have limited or systemic GPA, your doctor will likely prescribe corticosteroids (like prednisone) initially. These act quickly to bring down severe inflammation while the slower-acting medications take effect [4].

Additionally, because limited GPA involves severe local symptoms like nasal crusting and windpipe narrowing, you will likely need specialized local treatments. This can include daily saline rinses for your sinuses, topical medications, or procedures by an ENT to dilate a narrowed airway [6].

Common questions in this guide

What is the main difference between limited and systemic GPA?
The main difference depends on which organs are affected. Limited GPA is typically confined to the respiratory tract, such as the nose, sinuses, ears, and lungs. Systemic GPA is more widespread and affects major internal organs, especially causing dangerous inflammation in the kidneys.
Can limited GPA turn into systemic GPA?
Yes, limited GPA can progress to systemic GPA over time. Research shows that about 23% of patients with limited disease eventually develop systemic involvement, which is why routine monitoring of kidney function is so important.
How do ANCA blood tests differ between limited and systemic GPA?
Most patients with systemic GPA test positive for PR3-ANCA autoantibodies. In contrast, patients with limited GPA are much more likely to test negative for ANCA antibodies, which can sometimes make the condition harder to diagnose quickly.
Are treatments different for limited versus systemic GPA?
Because systemic GPA aggressively threatens the kidneys, it typically requires strong, fast-acting immunosuppressants like rituximab or cyclophosphamide right away. Limited GPA may initially be treated with less aggressive medications like methotrexate, alongside local treatments for sinus symptoms.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my current symptoms, would you classify my GPA as limited or systemic?
  2. 2.What was my exact ANCA test result (PR3-ANCA, MPO-ANCA, or negative), and how does that impact my diagnosis?
  3. 3.How frequently will we need to do routine blood and urine tests to monitor for kidney involvement?
  4. 4.Should I add an ENT (Ear, Nose, and Throat) specialist to my care team to help manage my sinus and airway symptoms?
  5. 5.If my limited GPA does not respond well to methotrexate, what is our next step for medication?
  6. 6.Are there any local treatments or daily routines, like sinus rinses, that I should be doing to manage my upper respiratory symptoms?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Evolving Concepts in Treatment.

    Lynch JP, Derhovanessian A, Tazelaar H, Belperio JA

    Seminars in respiratory and critical care medicine 2018; (39(4)):434-458 doi:10.1055/s-0038-1660874.

    PMID: 30404111
  2. 2

    Ear, nose and throat involvement in granulomatosis with polyangiitis: how it presents and how it determines disease severity and long-term outcomes.

    Felicetti M, Cazzador D, Padoan R, et al.

    Clinical rheumatology 2018; (37(4)):1075-1083 doi:10.1007/s10067-018-4019-0.

    PMID: 29460094
  3. 3

    Granulomatosis With Polyangiitis: A Clinical Case.

    Rodrigues F, Oliveira Sá AI, Mendes M, et al.

    Cureus 2022; (14(12)):e32410 doi:10.7759/cureus.32410.

    PMID: 36636531
  4. 4

    Localized versus systemic granulomatosis with polyangiitis: data from the French Vasculitis Study Group Registry.

    Iudici M, Pagnoux C, Courvoisier DS, et al.

    Rheumatology (Oxford, England) 2022; (61(6)):2464-2471 doi:10.1093/rheumatology/keab719.

    PMID: 34542599
  5. 5

    Granulomatous vasculitis.

    Marzano AV, Balice Y, Tavecchio S, et al.

    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 2015; (150(2)):193-202.

    PMID: 25791629
  6. 6

    Clinic manifestations in granulomatosis with polyangiitis.

    Greco A, Marinelli C, Fusconi M, et al.

    International journal of immunopathology and pharmacology 2016; (29(2)):151-9 doi:10.1177/0394632015617063.

    PMID: 26684637
  7. 7

    Localized Granulomatous with Polyangiitis (GPA): Varied Clinical Presentations and Update on Treatment.

    Sattui SE, Lally L

    Current allergy and asthma reports 2020; (20(10)):56 doi:10.1007/s11882-020-00953-1.

    PMID: 32648055
  8. 8

    Clinical associations of renal involvement in ANCA-associated vasculitis.

    Kronbichler A, Shin JI, Lee KH, et al.

    Autoimmunity reviews 2020; (19(4)):102495 doi:10.1016/j.autrev.2020.102495.

    PMID: 32068190
  9. 9

    Diagnosis and management of ANCA-associated vasculitis.

    Kronbichler A, Bajema IM, Bruchfeld A, et al.

    Lancet (London, England) 2024; (403(10427)):683-698 doi:10.1016/S0140-6736(23)01736-1.

    PMID: 38368016
  10. 10

    Granulomatosis with polyangiitis in pregnancy - clinical implications and treatment possibilities.

    Grygiel-Górniak B, Puszczewicz M

    European review for medical and pharmacological sciences 2015; (19(13)):2331-5.

    PMID: 26214766
  11. 11

    Comparative investigation of respiratory tract involvement in granulomatosis with polyangiitis between PR3-ANCA positive and MPO-ANCA positive cases: a retrospective cohort study.

    Ikeda S, Arita M, Misaki K, et al.

    BMC pulmonary medicine 2015; (15()):78 doi:10.1186/s12890-015-0068-1.

    PMID: 26223225
  12. 12

    [Granulomatosis with polyangiitis].

    Kerstein A, Holl-Ulrich K, Müller A, et al.

    Deutsche medizinische Wochenschrift (1946) 2017; (142(1)):24-31 doi:10.1055/s-0042-111610.

    PMID: 28056474
  13. 13

    Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets.

    Miloslavsky EM, Lu N, Unizony S, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2016; (68(12)):2945-2952 doi:10.1002/art.39812.

    PMID: 27428559
  14. 14

    Myeloperoxidase-ANCA-positive granulomatosis with polyangiitis is a distinct subset of ANCA-associated vasculitis: A retrospective analysis of 455 patients from a single center in China.

    Chang DY, Li ZY, Chen M, Zhao MH

    Seminars in arthritis and rheumatism 2019; (48(4)):701-706 doi:10.1016/j.semarthrit.2018.05.003.

    PMID: 29887327
  15. 15

    Comparative study of granulomatosis with polyangiitis subsets according to ANCA status: data from the French Vasculitis Study Group Registry.

    Puéchal X, Iudici M, Pagnoux C, et al.

    RMD open 2022; (8(1)) doi:10.1136/rmdopen-2021-002160.

    PMID: 35296533
  16. 16

    Dynamically changing antineutrophil cytoplasmic antibodies in granulomatosis with polyangiitis: A case report.

    Zhang Y, Dai QD, Wang JA, et al.

    World journal of clinical cases 2024; (12(16)):2881-2886 doi:10.12998/wjcc.v12.i16.2881.

    PMID: 38899312
  17. 17

    Updates in ANCA-associated vasculitis.

    Pagnoux C

    European journal of rheumatology 2016; (3(3)):122-133 doi:10.5152/eurjrheum.2015.0043.

    PMID: 27733943
  18. 18

    Granulomatosis with polyangiitis presenting with rare urogenital involvement: a case based review.

    Muklewicz N, Tadulewicz I, Aponowicz I, et al.

    Rheumatology international 2026; (46(7)).

    PMID: 42329457

This page is for educational purposes only and does not replace professional medical advice. Always consult your rheumatologist or care team to discuss your specific GPA symptoms, organ involvement, and treatment plan.

Get notified when new evidence is published on Granulomatosis with polyangiitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.